5 Key Takeaways
-
1
Astellas's ASP7317 shows potential for vision improvement in advanced geographic atrophy through subretinal RPE cell transplantation.
-
2
The phase 1b study involved 14 patients with severe vision impairment, demonstrating visual gains across all dose cohorts.
-
3
At 26 weeks, treated eyes had a mean BCVA improvement of +10.5 letters in the low-dose cohort, compared to declines in untreated eyes.
-
4
Improvements in best-corrected visual acuity persisted at 52 weeks, with medium-dose cohort showing a mean gain of 9 letters.
-
5
The study indicates a potential shift in AMD treatment from preservation to restoration of retinal function through regenerative therapy.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.